B

Bio-FD&C Co Ltd
KOSDAQ:251120

Watchlist Manager
Bio-FD&C Co Ltd
KOSDAQ:251120
Watchlist
Price: 13 820 KRW 2.37% Market Closed
Market Cap: 117.9B KRW
Have any thoughts about
Bio-FD&C Co Ltd?
Write Note

EV/EBIT
Enterprise Value to EBIT

15.6
Current
17.8
Median
4
Industry
Lower than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
15.6
=
Enterprise Value
75.2B KRW
/
EBIT
4.8B KRW
All Countries
Close
Market Cap EV/EBIT
KR
Bio-FD&C Co Ltd
KOSDAQ:251120
117.9B KRW 15.6
FR
Pharnext SCA
OTC:PNEXF
6T USD -216 971.5
US
Abbvie Inc
NYSE:ABBV
310.3B USD 23.4
US
Amgen Inc
NASDAQ:AMGN
141.6B USD 30.4
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD 10.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD 22.1
US
Epizyme Inc
F:EPE
94.1B EUR -501.1
AU
CSL Ltd
ASX:CSL
134.4B AUD 24.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD 16.7
US
Seagen Inc
F:SGT
39.3B EUR -53
NL
argenx SE
XBRU:ARGX
35.8B EUR -79.3
EBIT Growth EV/EBIT to Growth
KR
B
Bio-FD&C Co Ltd
KOSDAQ:251120
Average EV/EBIT: 20.4
15.6
71%
0.2
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 971.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
90%
0.3
US
Amgen Inc
NASDAQ:AMGN
30.4
90%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
32%
0.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.1
45%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -501.1 N/A N/A
AU
CSL Ltd
ASX:CSL
24.6
54%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.7
42%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -79.3 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
13.5
2-Years Forward
EV/EBIT
11.4
3-Years Forward
EV/EBIT
8.8

See Also

Discover More